Eli Lilly and Company’s mirikizumab demonstrated superior histologic response compared to placebo and Stelara (ustekinumab) in a Phase 3 study for moderately to severely active Crohn’s disease. The drug showed a significant improvement in mucosal healing and a favorable safety profile, potentially offering a new treatment option for patients struggling with this chronic inflammatory bowel disease.